Drug Profile
S 49076
Alternative Names: S49076Latest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Proto-oncogene protein c-met inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glioblastoma; Non-small cell lung cancer
- No development reported Liver cancer
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Liver-cancer in France
- 19 Oct 2018 Safety and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
- 03 Nov 2016 Servier completes a phase-I/II trial in Glioblastoma (Second-line therapy or greater, Recurrent, Combination therapy, Late-stage disease) in France and Switzerland (PO) (ISRCTN11619481)